CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 269 enrolled
Drug / intervention
Celecoxib +3 moredrug
Likely dose
Celecoxib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00402987
NCT00402987Phase 3Completed
CompareCT.gov

A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED COMPARISON OF THE EFFICACY, SAFETY, AND TOLERABILITY OF CELECOXIB 100-150 MG, INCLUDING INITIAL DOSES OF 50 AND 100 MG, AND PLACEBO IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH PAINFUL PHARYNGITIS

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Nov 23, 2006·Updated Mar 3, 2021

In Brief

A Phase 3 clinical trial evaluating Celecoxib, celecoxib, and 1 other intervention for Pharyngitis. Completed, enrolled 269 participants across 1 site.

Detailed Summary

We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharyngitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 23, 2006
Enrollment StartDec 4, 2006
Primary CompletionNov 15, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.6 years ago

Interventions

Celecoxibdrug

dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

Celecoxibdrug

dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo

celecoxibdrug

dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

placebodrug

dose 1 placebo followed 6-12 hours later by dose 2 placebo